Sinopharm Modern Reports H1 2026 Revenue RMB3.94 Billion, Down 19.22%; Net Profit RMB276 Million, Down 58.99%
Sinopharm Modern reported H1 2026 revenue of RMB3.94 billion, down 19.22% year on year, and net profit attributable to shareholders of RMB276 million, down 58.99%. Basic EPS was RMB0.2055. The company proposed a cash dividend of RMB0.5 per 10 shares. Pharmaceutical intermediates and APIs revenue fell 18.01% to RMB1.906 billion, representing 48.38% of total revenue. Sales of D-7ACA and penicillin V potassium surged 307.34% and 113.93%, while 6-APA and 7-ACA declined.
Sinopharm Modern disclosed its interim report for the first half of 2026. During the reporting period, the company achieved operating revenue of RMB3.94 billion, down 19.22% year on year; net profit attributable to shareholders of the listed company was RMB276 million, down 58.99%; basic earnings per share were RMB0.2055. The company plans to distribute a cash dividend of RMB0.5 per 10 shares (tax inclusive).
By segment, the pharmaceutical intermediates and APIs segment generated sales revenue of RMB1.906 billion, down 18.01% from the same period in 2025, accounting for 48.38% of current-period operating revenue, an increase of 0.72 percentage points from the same period in 2025. Sales volumes of certain major products grew year on year, with D-7ACA and penicillin V potassium volumes up 307.34% and 113.93% respectively, penicillin industrial potassium salt and ampicillin volumes each up more than 30%, amoxicillin volume up 11%, and biochemical specialty APIs volume up 25%. Meanwhile, volumes of products such as 6-APA and 7-ACA declined year on year.